Comparison

Amycretin vs. Lixisenatide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Amycretin	Lixisenatide
Germany	Unapproved	Prescription
JP	—	Prescription
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Amycretin and Lixisenatide?: Amycretin is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Lixisenatide?: The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Lixisenatide in Germany and the United States?: Germany: Amycretin — Unapproved, Lixisenatide — Prescription. United States: Amycretin — Unapproved, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Lixisenatide

Germany

Unapproved

Prescription

—

Prescription

United States

Unapproved

Frequently asked questions

What is the difference between Amycretin and Lixisenatide?

Amycretin is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Lixisenatide?

The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Lixisenatide in Germany and the United States?

Germany: Amycretin — Unapproved, Lixisenatide — Prescription. United States: Amycretin — Unapproved, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.